Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome

Mogamulizumab (MOGA), an anti-CCR4 monoclonal antibody, improves progression-free survival (PFS) and overall survival in Sézary syndrome (SS). Recently, a multicentre retrospective study conducted by the French Cutaneous Lymphoma study group assessed PFS in 52 patients with SS (median age 73 years, 56% female sex, 75% stage IVA1) who discontinued MOGA for reasons other than disease progression (Moga-stop Study). We report data from an extended follow-up of this cohort, along with comparative PFS outcomes from a parallel SS cohort with continuous MOGA treatment until progression.